Section Arrow
SGMT.NASDAQ
- Sagimet Biosciences
Quotes are at least 15-min delayed:2025/09/06 00:33 EDT
Regular Hours
Last
 7.11
-0.14 (-1.93%)
Day High 
7.285 
Prev. Close
7.25 
1-M High
10.0624 
Volume 
381.82K 
Bid
7
Ask
7.2
Day Low
7.0104 
Open
7.23 
1-M Low
6.5323 
Market Cap 
235.78M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 7.34 
20-SMA 7.85 
50-SMA 8.58 
52-W High 11.41 
52-W Low 1.73 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.86/-2.14
Enterprise Value
235.78M
Balance Sheet
Book Value Per Share
4.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GNPXGenprex0.2295+0.0738+47.40%0.18PE
ADAPAdaptimmune Therapeutics plc0.041-0.01-19.61%-- 
NUVBNuvation Bio3.9+0.48+14.04%-- 
KLTOKlotho Neurosciences Inc0.4851-0.0099-2.00%-- 
IOVAIovance Biotherapeutics2.49+0.29+13.18%-- 
Quotes are at least 15-min delayed:2025/09/06 00:33 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.